I-Mab (IMAB)
| Market Cap | 78.99M |
| Revenue (ttm) | 569,464 |
| Net Income (ttm) | -62.56M |
| Shares Out | 81.43M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228,029 |
| Open | 0.970 |
| Previous Close | 0.967 |
| Day's Range | 0.962 - 0.998 |
| 52-Week Range | 0.841 - 2.000 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+724.74%) |
| Earnings Date | Mar 13, 2025 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for IMAB stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 724.74% from the latest price.
News
I-Mab to Participate in Leerink Partners Global Healthcare Conference
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents f...
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treat...
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) ROCKVILLE, Md. , Jan. 8, 2025 /PRNewswire/ -- I-Mab (N...
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose e...
I-Mab to Participate at the Piper Sandler Healthcare Conference
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md. , Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech compa...
I-Mab Reports Third Quarter 2024 Results
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 A...
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies...
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies...
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASD...
I-Mab to Participate at the Truist Securities BioPharma Symposium
ROCKVILLE, Md. , Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatm...
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers...
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlatio...
I-MAB (IMAB) Q2 2024 Earnings Call Transcript
I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET Company Participants Sean Fu - Chief Executive Officer (interim) Phillip Dennis - Chief Medical Officer Josep...
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bri...
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md. , Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies...
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB...
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md. , Aug. 7, 2024 /PRNewswire/ -- I...
I-Mab Announces Leadership Transitions
ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has app...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...
I-Mab to Participate at the Jefferies Global Healthcare Conference
ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated...
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat...
I-Mab Announces Closing of the Divestiture of Business Operations in China
ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high...
I-Mab Reports Full Year 2023 Financial Results and Business Update
Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (...